THERALUGAND
LIVE

Serial Number

79383213

Owner

Eckert & Ziegler Radiopharma GmbH

Attorney

Ursula B. Day

Filing Date

Jun 22, 2023

Add to watchlist:

No watchlists yet
View on USPTO

THERALUGAND Trademark

Serial Number: 79383213 • Registration: 7602399

THERALUGAND is a trademark filed by Eckert & Ziegler Radiopharma GmbH on June 22, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Eckert & Ziegler Radiopharma GmbH (2 trademarks)

Robert-Rössle-Str. 10

Entity Type: 16

Trademark Details

Filing Date

June 22, 2023

Registration Date

December 17, 2024

Published for Opposition

October 29, 2024

Goods & Services

Science and technology services, namely, scientific research services; testing, authentication and quality control, namely, testing of pharmaceuticals, quality control for others; bacteriological consultation and research; consultancy in the field of pharmaceutical research; consultancy relating to laboratory testing of materials; biological research, clinical research in the field of chemotherapy and medical research; medical research laboratory services; analysis of human serum for medical research; research and development in the pharmaceutical and biotechnology fields; medical research laboratory services relating to the production of monoclonal antibodies; research and development services in the field of antibodies; pharmaceutical research and development; consultancy relating to biotechnology; biochemical analysis; biochemistry research services; biological research; microbiological testing; preparation of scientific research reports in the biotechnology field; research and development services in the field of immunology

Industrial chemicals; radioactive elements for scientific purposes; detergents for use in manufacture of radioactive substances; salts for industrial purposes; chemical substances for analyses in laboratories, other than for medical or veterinary purposes; diagnostic preparations, other than for medical or veterinary purposes; isotopes for industrial purposes; chemical reagents other than for medical or veterinary purposes; salts being chemical preparations, namely, industrial salts; fissionable chemical elements, namely, radioactive elements for scientific purposes; emollients for industrial purposes; enzymes for scientific purposes; dyes for scientific or research purposes; glycoprotein; immunoglobulins, being biological preparations for scientific use, other than for medical use; immunoassay reagents for scientific purposes, other than for medical use; immunological antibodies for scientific purposes, other than for medical use; biomolecule labeling kits comprising reagents for use in scientific research; laboratory reagents for scientific use; tagged antibodies for scientific use; tagged antibodies for laboratory use; monoclonal antibodies for scientific use; proteins in raw form for use in science; proteins in raw form for scientific purposes for binding antibodies other than for medical use; reagents for scientific purposes; substances for scientific use, namely, radioactive substances; universal reagents for automated test systems for scientific purposes; diagnostic reagents for scientific or research use

Medical and veterinary preparations, namely, radioactive preparations for use in treating cancer; biological reagents for medical use; biological reagents for veterinary use; diagnostic chemical reagents for medical use; diagnostic agents for pharmaceutical use; diagnostic biomarker reagents for medical purposes; immunoassay reagents for medical use; in vitro diagnostic preparations for medical use; clinical medical reagents; diagnostic reagents for medical use; clinical diagnostic reagents for medical or veterinary purposes; reagents for use in diagnostic pregnancy tests for medical or veterinary purposes; reagents and media for medical and veterinary diagnostic purposes; reagents for microbiological analysis for medical purposes; mineral salts for medical purposes; chemical preparations for medical purposes, namely, for treatment of hormonal imbalances; chemical preparations for pharmaceutical purposes, namely, for treatment of migraines; chemical preparations for veterinary purposes, namely, chemical reagents for veterinary use; chemico-pharmaceutical preparations for the treatment of gout; disinfectants; diagnostic preparations for medical use; pharmaceutical, veterinary and sanitary preparations for treatment of tumor diseases; radioactive substances for medical purposes

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Jun 21, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
May 31, 2025 FICS
FINAL DISPOSITION PROCESSED
May 31, 2025 FIMP
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
May 3, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 15, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Apr 15, 2025 OPNR
NEW REPRESENTATIVE AT IB RECEIVED
Mar 21, 2025 NREP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Mar 18, 2025 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Dec 17, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Dec 17, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 29, 2024 NPUB
PUBLISHED FOR OPPOSITION
Oct 29, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 9, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 18, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Sep 16, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sep 16, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Sep 16, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Sep 16, 2024 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
Sep 12, 2024 GNFN
FINAL REFUSAL E-MAILED
Sep 12, 2024 GNFR
FINAL REFUSAL WRITTEN
Sep 12, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 10, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 9, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 9, 2024 TROA
REFUSAL PROCESSED BY IB
Apr 24, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Apr 3, 2024 RFCS
REFUSAL PROCESSED BY MPU
Apr 2, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 14, 2024 RFCR
NON-FINAL ACTION WRITTEN
Mar 13, 2024 CNRT
ASSIGNED TO EXAMINER
Mar 11, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Nov 21, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 17, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Nov 16, 2023 REPR